Orbit Genomics is building the genomic foundation for accurate, non-invasive diagnosis and precision intervention across complex diseases through its patented, AI-powered OrbiSeq™ technology. OrbiSeq is a scalable genomics engine that enables genome-wide analysis of repetitive DNA—specifically short tandem repeats (STRs)—a previously inaccessible and highly informative class of genetic variation with broad relevance to disease diagnosis, risk stratification, precision intervention and longevity.

The company’s lead product, OrbiSeq-L, is a non-invasive diagnostic test for early-stage lung cancer designed to accurately diagnose patients with indeterminate pulmonary nodules (IPNs). OrbiSeq-L is the first blood test accurate enough to diagnose early-stage cancer—not just detect it—replacing invasive and costly biopsies.

Lung cancer is the deadliest form of cancer largely because it is diagnosed too late. By enabling accurate, early diagnosis through a simple blood test, Orbit Genomics is launching a focused first product while establishing a platform for rapid expansion across cancer, cardiovascular and neurological diseases, as well as applications in healthy aging and longevity.